loading page

Dulaglutide preserves kidney function and maintains metabolic control at a 36-month follow-up
  • +5
  • David Leon-Jimenez ,
  • Ricardo Martín Usategui ,
  • Fernando Moreno Obregón ,
  • Luis Miguel Álvarez Aragón ,
  • María Dolores López Carmona,
  • Tamara García Garrido ,
  • Leopoldo Pérez de Isla ,
  • José Pablo Miramontes-González
David Leon-Jimenez
Virgen del Rocio University Hospital
Author Profile
Ricardo Martín Usategui
Universidad de Valladolid
Author Profile
Fernando Moreno Obregón
Primary Health Care, Cartaya
Author Profile
Luis Miguel Álvarez Aragón
Hospital la Merced
Author Profile
María Dolores López Carmona
Hospital Regional Universitario Carlos Haya
Author Profile
Tamara García Garrido
Hospital Virgen del Puerto
Author Profile
Leopoldo Pérez de Isla
San Carlos University Hospital Cardiovascular Institute
Author Profile
José Pablo Miramontes-González
Rio Hortega University Hospital
Author Profile

Abstract

The renal benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RA) are based mainly on preservation of glomerular filtration and a reduction in macroalbuminuria. In controlled studies dulaglutide has shown good metabolic rate and slows the progression of glomerular filtration rate (GFR) loss. We analyzed, the metabolic control, the renal preservation data based on estimated GFR (eGFR) and the relationship of eGFR changes with baseline values at 36 months (M) follow–up. The results shows: glycated hemoglobin was reduced −1.4% at 12M, (p<0.001), fasting blood glucose showed a significant reduction (−30 mg/dL) at 12M (p=0.005), weight showed a 3.6 kg reduction at 12M (p=0.009). GFR did not show a worsening during follow-up: baseline value was 88.10±26.47 ml/min/1.73m2 and remained stable (83.25±29.27 ml/min/1.73m2; p=0.134) at the end of the study. Based on the 36M follow-up results, dulaglutide was shown to be an effective and nephroprotective drug in diabetic patients.